MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517056341 A) filed by Takeda Pharmaceutical Company Limited, Osaka, Japan, on June 11, for 'heterocyclic compound and use thereof.'
Inventor(s) include Kina, Asato; Ikeda, Zenichi; Kono, Mitsunori; Oguro, Yuyaap; Kubo, Osamu; Yamashita, Toru; Takami, Kazuaki; Yukawa, Takafumi; Seto, Masaki; Kamata, Makoto; Sato, Kenjiro; Murakami, Masataka; Sasaki, Yusuke; Reynolds, Matthew Thomas; Nakamura, Minoru; Kamei, Taku; Kakei, Hiroyuki; Yamaguchi, Fumie; Ohashi, Tomohiro; Kojima, Takuto; Kakegawa, Keiko; Pnner, Florian; Nakamura, Shinji; Morishita, Nao; Hidaka, Tadashi; Takashima, Sachie; and Taniguchi, Takahiko.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy."
The patent application was internationally filed on Nov. 29, 2023, under International application No.PCT/IB2023/062016.
Disclaimer: Curated by HT Syndication.
